Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease);Familie mit ausgeprägter hyperferritinämie als folge einer hämochromatose typ 4 (ferroportin-krankheit)

Zeitschrift fur Gastroenterologie

Volumn 52, Issue 9, 2014, Pages 1075-1080

  Muehlenberg, Klaus ^a   Faltermeier, N ^a   Lohse, P ^b   Tannapfel, A ^c   Pech, O ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Institut für Laboratoriumsmedizin und Molekulargenetik   (Germany)

^c INSTITUT FÜR PATHOLOGIE   (Germany)

Author keywords

Haemochromatosis type 4; Hyperferritinaemia; Magnetic resonance imaging; Mutation; SLC40A1 gene

Indexed keywords

FERRITIN; SLC40A1 PROTEIN; SOLUTE CARRIER FAMILY 4; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CASE REPORT; FAMILY HISTORY; FEMALE; HEMOCHROMATOSIS; HEMOCHROMATOSIS TYPE 4; HUMAN; HYPERFERRITINEMIA; LIVER CIRRHOSIS; MIDDLE AGED; CATARACT; DIFFERENTIAL DIAGNOSIS; IRON METABOLISM DISORDERS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED, 80 AND OVER; CATARACT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOCHROMATOSIS; HUMANS; IRON METABOLISM DISORDERS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 84924447144     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0034-1366809     Document Type: Article

References (19)

1. Bacon B. R., Adams P. C., Kowdley K. V. et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology: 2011; 54 328 343
2. European Association For The Study Of The Liver EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol: 2010; 53 3 22
3. Mayr R., Janecke A. R., Schranz M. et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol: 2010; 53 941 949
4. Niederau C. Hereditary hemochromatosis. Med Klin (Munich): 2009; 104 931 946
5. Rosário C., Zandman-Goddard G., Meyron-Holtz E. G. et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med: 2013; 11 185
6. Adams P. C., Barton J. C. How I treat hemochromatosis. Blood: 2010; 116 317 325
7. Pietrangelo A., Corradini E., Ferrara F. et al. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol Dis: 2006; 37 192 196
8. Sondag M. J., Wattamwar A. S., Aleppo G. et al. Case 179: Hereditary hemochromatosis. Radiology: 2012; 262 1037 1041
9. Queiroz-Andrade M., Blasbalg R., Ortega C. D. et al. MR imaging findings of iron overload. Radiographics: 2009; 29 1575 1589
10. Castiella A., Alústiza J. M., Emparanza J. I. et al. Liver iron concentration quantification by MRI: are recommended protocols accurate enough for clinical practice? Eur Radiol: 2011; 21 114 137
11. Gandon Y., Olivie D., Guyader D. et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet: 2004; 363 357 360
12. Schimanski L. M., Drakesmith H., Merryweather-Clarke A. T. et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood: 2005; 105 4096 4102
13. Drakesmith H., Schimanski L. M., Ormerod E. et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood: 2005; 106 1092 1097
14. Wallace D. F., Clark R. M., Harley H. A. et al. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol: 2004; 40 710 713
15. Corradini E., Ferrara F., Pollicino T. et al. Disease progression and liver cancer in the ferroportin disease. Gut: 2007; 56 1030 1032
16. Le Lan C., Mosser A., Ropert M. et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology: 2011; 140 1199 1207
17. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology: 2010; 139 393 408
18. Mayr R., Griffiths W. J., Hermann M. et al. Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload. Gastroenterology: 2011; 140 2056 2063
19. Riad A. Point Mutations in Ferroportin Disease. In: (Hrsg) Colin L. Point Mutation. ISBN: 978-953-51-0331-8, Rijeka, Croatia, InTech: 2012; 286 300